SCHEMBL12373945

SCHEMBL12373945

CC(C)Oc1ccc(-c2nn(C)c3ccc(N)cc23)cn1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 2/20 0.42
PIK3CD O00329 1/20 0.42
PIK3CB P42338 1/20 0.42
PI4KA P42356 1/20 0.42
PIK3CG P48736 1/20 0.42
PI4KB Q9UBF8 1/20 0.42
SCN9A Q15858 3/20 0.41
PDE10A Q9Y233 1/20 0.41
SCN5A Q14524 1/20 0.39
SYK P43405 2/20 0.38
FLT3 P36888 1/20 0.38
MAPK1 P28482 3/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
NAMPT P43490 1/20 0.33
KHK P50053 1/20 0.33
CHRNA7 P36544 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LRRK2 Q5S007 1/20 0.33
HDAC8 Q9BY41 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12374209 0.83 MAPK13 (0.38) SYKFLT3MAPK1L3MBTL1KHK
SCHEMBL12374165 0.81 PIK3CA (0.44) PIK3CAPIK3CDPIK3CBPI4KAPIK3CG
SCHEMBL12373938 0.81 L3MBTL1 (0.60) PIK3CAPIK3CDPIK3CBPI4KAPIK3CG
SCHEMBL12373961 0.81 PIK3CA (0.37) PIK3CAPIK3CDPIK3CBPI4KAPIK3CG
SCHEMBL13854974 0.79 L3MBTL1 (0.38) PIK3CAPIK3CDPIK3CGSCN9ASCN5A
SCHEMBL21761646 0.76 PDE10A (0.38) PIK3CAPIK3CDPIK3CBPI4KAPIK3CG
SCHEMBL13495128 0.76 LRRK2 (0.52) PIK3CAPIK3CDPIK3CBPI4KAPIK3CG
SCHEMBL13354962 0.72 MAPK14 (0.47) SCN9AL3MBTL1NAMPTKHKALDH1A1
SCHEMBL12374194 0.72 LRRK2 (0.39) PIK3CAPDE10AL3MBTL1NAMPTKHK
SCHEMBL13854977 0.72 TTBK1 (0.39) PIK3CAPIK3CDPIK3CBPIK3CGL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180000803-A1 (S)-N-(3-(6-ISOPROPOXYPYRIDIN-3-YL)-1H-INDAZOL-5-YL)-1-(2-(4-(4-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H)-YL)-2-OXOETHYL)-3-(METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS MERCK SHARP & DOHME CORP. (US) 2018-01-04 US disclosed
US-20170362202-A1 (S)-N-(3-(6-ISOPROPOXYPYRIDIN-3-YL)-1H-INDAZOL-5-YL)-1-(2-(4-(4-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H)-YL)-2-OXOETHYL)-3-(METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS MERCK SHARP & DOHME CORP. (US) 2017-12-21 US disclosed
US-8716483-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2014-05-06 US disclosed
US-20110189192-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME LLC 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362202-A1 (S)-N-(3-(6-ISOPROPOXYPYRIDIN-3-YL)-1H-INDAZOL-5-YL)-1-(2-(4-(4-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H)-YL)-2-OXOETHYL)-3-(METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS HK1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HINT1 PIK3CA 1892/4885PIK3CD 2177/4885PIK3CB 1952/4885
US-20180000803-A1 (S)-N-(3-(6-ISOPROPOXYPYRIDIN-3-YL)-1H-INDAZOL-5-YL)-1-(2-(4-(4-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H)-YL)-2-OXOETHYL)-3-(METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS S100P, TSLP, TPSAB1 PIK3CA 725/4885PIK3CD 555/4885PIK3CB 614/4885
US-20110189192-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MAPK1, MAPK4, MAPK10 PIK3CA 162/4885PIK3CD 164/4885PIK3CB 194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.